The informal term "GLP-3" refers to a new triple-agonist drug that targets three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide, another naturally occurring hormone released by the gut after eating) and glucagon receptors
Second, human research is still in the development stage
Available from: (cited 2025 Jun 11)
In terms of weight loss outcomes, the TRIUMPH-1 trial suggests that Retatrutide may provide superior results, with up to a 28.3% weight loss over 80 weeks compared to tirzepatide's 20.9% achieved in other studies
3,5 In early T2DM managed with lifestyle alone, orforglipron lowered glycated hemoglobin A1c (HbA1c) by -1.24 to -1.48 percentage points over 40 weeks as compared to -0.41 with placebo, with no severe hypoglycemia reported and weight reduction ranging from 4.5% to 7.6%, 3 which led to mean HbA1c levels of 6.5-6.7%
R., Rosenstock, J., Terauchi, Y., et al